Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET

Company Participants

David DeMartino – Senior Vice President-Investor Relations
Ivan Tornos – President and Chief Executive Officer
Suketu Upadhyay – Chief Financial Officer and Executive Vice President-Finance, Operations and Supply Chain

Conference Call Participants

Travis Steed – Bank of America
Vik Chopra – Wells Fargo
David Roman – Goldman Sachs
Allen Gong – JPMorgan
Matthew O’Brien – Piper Sandler
Chris Pasquale – Nephron
Steve Lichtman – Oppenheimer
Sophia Knopp – Evercore ISI
Richard Newitter – Truist Securities
Jeff Johnson – Baird
Caitlin Cronin – Canaccord
Mike Matson – Needham & Company
Shagun Singh – RBC Capital Markets

Operator

Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Third Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, October 30, 2024. Following today's presentation there will be a question-and-answer session. At this time all participants are in a listen-only mode. [Operator Instructions]

I would now like to turn the conference over to David DeMartino, Senior Vice President of Investor Relations. Please go ahead.

David DeMartino

Thank you, operator, and good morning, everyone. Welcome to Zimmer Biomet's third quarter 2021 earnings conference call. Joining me on today's call are Ivan Tornos, our President and CEO; and CFO and EVP, Finance, Operations and Supply Chain, Suketu Upadhyay.

Before we get started, I'd like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by the forward-looking statements due to a variety of risks and uncertainties. Please note, we assume no obligation to update these forward-looking statements even if actual results or future expectations change materially.

Please refer to our SEC filings for a detailed discussion of these risks and uncertainties in addition to the inherent limitations of such forward-looking statements. Additionally, the discussions on this call will include certain non-GAAP financial measures. Some of which are forward-looking non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures and an explanation of our basis for calculating these measures is included within our second quarter earnings release, which can be found on our website, zimmerbiomet.com.

With that, I'll turn the call over to Ivan. Ivan?

Ivan Tornos

Good morning, everyone, and thank you for joining today's call. Welcome, David, to your very first Zimmer Biomet earnings call. It's truly lucky to have you. We love what you bring to the team already. I'd like to start today the way that I always do by taking a moment to recognize and to show my gratitude to the over 18,000 Zimmer Biomet team members who each and every day across the globe move for business and our mission forward. Thank you for your commitment to the organization. Thank you for your tireless work. Thank you for your very strong performance and most importantly thank you for what you do for our customers and patients every single day. As I said in the past, and as I will continue to say as long as I'm here, the Zimmer Biomet workforce and the culture that we have truly is one of our key competitive advantages.